Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Curr Opin Immunol. 2010 Jun;22(3):326-32. doi: 10.1016/j.coi.2010.01.001. Epub 2010 Jan 29.
Inducible costimulator (ICOS), a member of the CD28 family of costimulatory molecules, is upregulated on the surface of T cells following T cell activation and upon binding to its ligand (ICOSL), initiates a cascade of events that can shape key aspects of the immune response. Although initial studies focused on determining the role of ICOS in Th1 versus T helper 2 (Th2) responses, new insights into its biology have revealed the contribution of ICOS to germinal center formation and isotype switching, as well as its relevance to the fate and function of effector and regulatory CD4(+) T cells in the response against self (i.e., tumors) and non-self (i.e., bacterial, worm, and viral infections). This multiplicity of roles positions ICOS at the center of attention for immunotherapy where manipulation of this pathway could lead to novel approaches in the treatment of human diseases.
诱导共刺激分子(ICOS)是共刺激分子 CD28 家族的成员,在 T 细胞活化后其表面上调,并与配体(ICOSL)结合,启动一系列事件,可影响免疫反应的关键方面。虽然最初的研究集中在确定 ICOS 在 Th1 与 Th2 反应中的作用,但对其生物学的新认识揭示了 ICOS 对生发中心形成和同种型转换的贡献,以及其与效应器和调节性 CD4(+)T 细胞在针对自身(即肿瘤)和非自身(即细菌、蠕虫和病毒感染)的反应中的命运和功能的相关性。ICOS 的这种多重作用使其成为免疫治疗的关注焦点,通过操纵该途径可能为人类疾病的治疗带来新方法。